Apple Inc. v. Omni Medsci, Inc.

CourtCourt of Appeals for the Federal Circuit
DecidedJune 21, 2024
Docket23-1034
StatusUnpublished

This text of Apple Inc. v. Omni Medsci, Inc. (Apple Inc. v. Omni Medsci, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Apple Inc. v. Omni Medsci, Inc., (Fed. Cir. 2024).

Opinion

Case: 23-1034 Document: 44 Page: 1 Filed: 06/21/2024

NOTE: This disposition is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

APPLE INC., Appellant

v.

OMNI MEDSCI, INC., Appellee ______________________

2023-1034 ______________________

Appeal from the United States Patent and Trademark Office, Patent Trial and Appeal Board in No. IPR2021- 00453. ______________________

Decided: June 21, 2024 ______________________

JEFFREY PAUL KUSHAN, Sidley Austin LLP, Washing- ton, DC, argued for appellant. Also represented by THOMAS ANTHONY BROUGHAN, III, JOSHUA JOHN FOUGERE; MICHAEL ROBERTS, Dallas, TX.

THOMAS A. LEWRY, Brooks Kushman PC, Royal Oak, MI, argued for appellee. Also represented by JOHN S. LEROY, CHRISTOPHER C. SMITH. ______________________ Case: 23-1034 Document: 44 Page: 2 Filed: 06/21/2024

Before REYNA and CUNNINGHAM, Circuit Judges, and ALBRIGHT, District Judge 1. ALBRIGHT, District Judge. Appellant Apple Inc. appeals from a Final Written De- cision of the Patent Trial and Appeal Board finding Apple failed to show that claims 3–6 and 8–14 of U.S. Patent No. 10,517,484 were unpatentable. 2 Those claims were upheld because the Board found prior art did not disclose the claim limitation “configured to identify an object” (the “identify- ing limitation”). In contrast, the Board found claim 16 un- patentable, which is like upheld claims 3 and 8 except for the claim limitation “configured to detect an object” (the “detecting limitation”). Apple appeals on two grounds, one substantive and one procedural. First, Apple claims that the Board incorrectly construed the identifying limitation. Second, Apple argued below that U.S. Patent No. 9,241,676 (“Lisogurski”) and U.S. Patent No. 8,108,036 (“Tran”) disclose the identifying limitation even under appellee Omni MedSci, Inc.’s pro- posed construction (the “alternative argument”). Apple faults the Board for considering this an improper new reply argument. Because the Board erred only in disregarding the alternative argument, we affirm-in-part, vacate-in- part, and remand to the Board for further consideration.

1 Honorable Alan D Albright, District Judge, United States District Court for the Western District of Texas, sit- ting by designation. 2 The Board found unpatentable several other claims of the ’484 patent. However, appellee Omni MedSci, Inc. does not appeal any aspect of the Final Written Decision, including the Board’s unpatentability finding on claim 16 or its claim constructions. Case: 23-1034 Document: 44 Page: 3 Filed: 06/21/2024

APPLE INC. v. OMNI MEDSCI, INC. 3

BACKGROUND I Omni MedSci, Inc. is the assignee of U.S. Patent No. 10,517,484, entitled “Semiconductor Diodes-based Physio- logical Measurement Device with Improved Signal-to- Noise Ratio.” The patent is generally directed to a “weara- ble device includ[ing] a measurement device to measure a physiological parameter adapted to be placed on a wrist or an ear of a user.” ’484 patent, at [57]. The wearable device measures the physiological parameter by emitting light and analyzing the light that is reflected back. See id. The specification has sections corresponding to various blood constituents of potential interest, such as glucose, ketones, and hemoglobin A1c. Id. at 11:20; 13:1; 14:23. Claims 3, 8, and 16 are relevant to the arguments pre- sented in this appeal. Although each depends on a differ- ent independent claim, none of the limitations of any independent claim—or any claim upon which claims 3, 8, or 16 depend—are at issue. The three claims state: 3. The system of claim 2, wherein the wearable device is at least in part configured to identify an object, and to compare a property of at least some of the output signal to a threshold. 8. The system of claim 7, wherein the wearable device is at least in part configured to identify an object, and a property of at least some of the output signal is compared by at least one of the wearable device, the smart phone or tablet to a threshold. 16. The system of claim 15, wherein the weara- ble device is at least in part configured to detect an object, and a property of at least some of the output signal is compared to a threshold. ’484 patent, 37:43–46; 38:63–67; 40:33–36 (emphases added). Case: 23-1034 Document: 44 Page: 4 Filed: 06/21/2024

II A Apple petitioned to institute an inter partes review of claims 1–23 of the ’484 patent. J.A. 203, 220. One ground is relevant to this appeal. Apple argued that the combina- tion of prior art references Lisogurski, Tran, and U.S. Pa- tent Application Publication No. 2005/00494468 (“Carlson”) rendered claims 3, 8, and 16 (among others) ob- vious. J.A. 220. For the identifying and detecting limita- tions, Apple argued that Lisogurski discloses sending an error signal when its sensor has fallen off the subject— which requires identifying and detecting when an object, such as a wrist or an ear, is in range of the sensor. J.A. 275. For the limitation “configured . . . to compare a prop- erty of at least some of the output signal to a threshold,” the petition claimed that Lisogurski discloses comparing detected signals, such as blood oxygen saturation, to thresholds or target values. J.A. 276. Similarly, the peti- tion argued that Tran discloses monitoring health infor- mation, such as pulse oximetry measurements, and comparing it to user-provided parameters for generating health alerts. J.A. 271, 276. Neither the petition nor the patent owner’s preliminary response discussed the identi- fying or detecting limitations in their claim construction sections. J.A. 232–34; 4761–62. The Board instituted the IPR. J.A. 5162. The institu- tion decision did not construe the identifying and detecting limitations. See J.A. 5169–70. Omni’s patent owner response disputed, for the first time, the construction of the “identify an object” limitation in Claims 3 and 8 and the “detect an object” limitation in Claim 16. J.A. 5242–45. For the “identify an object” limi- tation, Omni proposed the construction “to recognize or es- tablish an object as being a particular thing.” J.A. 5244. For the “detect an object” limitation, Omni proposed the construction “to discover or notice the existence or presence Case: 23-1034 Document: 44 Page: 5 Filed: 06/21/2024

APPLE INC. v. OMNI MEDSCI, INC. 5

of something.” J.A. 5245. The proposed constructions were based off the Random House Kernerman Webster’s College Dictionary (2010). J.A. 5242; 5244. In both cases, Omni argued that the ’484 patent claims and specification con- firmed the dictionary-based plain meaning. J.A. 5242–45. In its reply brief, Apple argued that the terms of the identifying and detecting limitations were commonly un- derstood and needed no construction. J.A. 5378. To the extent construction was necessary, Apple proposed the same construction for both limitations: “to discover or de- termine the existence, presence, or fact of an object.” J.A. 5378–79. For the “identify an object” limitation, Apple ar- gued that its construction aligned with the claims and spec- ification, which use the term “identify” to confirm that an object is present or not, rather than to take action depend- ent on what the object is. J.A. 5379. Apple argued that Lisogurski discloses both the identifying and detecting an object limitations based on Apple’s proposed construction. J.A. 5381–82. Apple also argued in its reply brief that Lisogurski and Tran disclose the identifying limitation even under Omni’s proposed construction. J.A. 5383. Apple pointed to Li- sogurski and Tran’s techniques for measuring blood oxygen saturation and other blood constituents, id., which Apple relied on in the petition to show “compar[ing] a property of at least some of the output signal to a threshold.” J.A. 275– 76.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Baran v. Medical Device Technologies, Inc.
616 F.3d 1309 (Federal Circuit, 2010)
Powell v. Home Depot U.S.A., Inc.
663 F.3d 1221 (Federal Circuit, 2011)
Thorner v. Sony Computer Entertainment America LLC
669 F.3d 1362 (Federal Circuit, 2012)
Aspex Eyewear, Inc. v. Marchon Eyewear, Inc.
672 F.3d 1335 (Federal Circuit, 2012)
Sas Institute, Inc. v. Complementsoft, LLC.
825 F.3d 1341 (Federal Circuit, 2016)
SAS Institute Inc. v. Iancu
584 U.S. 357 (Supreme Court, 2018)
Acceleration Bay, LLC v. Activision Blizzard Inc.
908 F.3d 765 (Federal Circuit, 2018)
Hamilton Beach Brands, Inc. v. F'real Foods, LLC
908 F.3d 1328 (Federal Circuit, 2018)
Seabed Geosolutions (Us) Inc. v. Magseis Ff LLC
8 F.4th 1285 (Federal Circuit, 2021)
Dionex Softron Gmbh v. Agilent Technologies, Inc.
56 F.4th 1353 (Federal Circuit, 2023)
Google LLC v. Ecofactor, Inc.
92 F.4th 1049 (Federal Circuit, 2024)

Cite This Page — Counsel Stack

Bluebook (online)
Apple Inc. v. Omni Medsci, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/apple-inc-v-omni-medsci-inc-cafc-2024.